EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer

Sander Mertens, Maarten A Huismans, Carla S Verissimo, Bas Ponsioen, Rene Overmeer, Natalie Proost, Olaf van Tellingen, Marieke van de Ven, Harry Begthel, Sylvia F Boj, Hans Clevers, Jeanine M L Roodhart und 2 weitere

Cell Reports · 2023-04 · 42 (4) · 112324

DOI: 10.1016/j.celrep.2023.112324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2023-04. Verfasst von Sander Mertens und 13 weiteren Autor:innen. Beteiligte Einrichtung: Oncode Institute, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organisation for Scientific Research, European Research Council, AACR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patient-derived organoids (PDOs) are widely heralded as a drug-screening platform to develop new anti-cancer therapies. Here, we use a drug-repurposing library to screen PDOs of colorectal cancer (CRC) to identify hidden vulnerabilities within therapy-induced phenotypes. Using a microscopy-based screen that accurately scores drug-induced cell killing, we have tested 414 putative anti-cancer drugs for their ability to switch the EGFRi/MEKi-induced cytostatic phenotype toward cytotoxicity. A majority of validated hits (9/37) are microtubule-targeting agents that are commonly used in clinical oncology, such as taxanes and vinca-alkaloids. One of these drugs, vinorelbine, is consistently effective across a panel of >25 different CRC PDOs, independent of RAS mutational status. Unlike vinorelbine alone, its combination with EGFR/MEK inhibition induces apoptosis at all stages of the cell cycle and shows tolerability and effective anti-tumor activity in vivo, setting the basis for a clinical trial to treat patients with metastatic RAS-mutant CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsAntineoplastic AgentsHumansProto-Oncogene Proteins p21(ras)VinorelbineDrug RepositioningCell Line, TumorOrganoids

Stichwörter der Autor:innen

CP: CancerCP: Stem cell researchcolorectal cancerimage-based drug screeningmicrotubule-targeting agentsorganoidstargeted therapy

Substanzen

Proto-Oncogene Proteins p21(ras)VinorelbineAntineoplastic AgentsKRAS protein, human

Autor:innen und Institutionen

  • Oncode Institute, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Hubrecht Organoid Technology (HUB), Utrecht, the Netherlands.
  • Mouse Clinic for Cancer and Aging Research (MCCA), Preclinical Intervention Unit, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Mouse Clinic for Cancer and Aging Research (MCCA), Preclinical Intervention Unit, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Division of Clinical Pharmacology, the Netherlands Cancer Institute…
  • Oncode Institute, Hubrecht Institute-KNAW, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Oncode Institute, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.

Förderung

  • Netherlands Organisation for Scientific Research
  • European Research Council
  • AACR
  • Dutch Cancer Society
  • Engineering Research Centers

Zitieren

APA

Mertens, S., Huismans, M. A., Verissimo, C. S., Ponsioen, B., Overmeer, R., Proost, N., van Tellingen, O., van de Ven, M., Begthel, H., Boj, S. F., Clevers, H., Roodhart, J. M. L., Bos, J. L., & Snippert, H. J. G. (2023). Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer. Cell Reports, 42(4), 112324. https://doi.org/10.1016/j.celrep.2023.112324

Vancouver

Mertens S, Huismans MA, Verissimo CS, Ponsioen B, Overmeer R, Proost N, et al. Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer. Cell Reports. 2023;42(4):112324. doi:10.1016/j.celrep.2023.112324

BibTeX
@article{Mertens2023,
  author = {Mertens, Sander and Huismans, Maarten A and Verissimo, Carla S and Ponsioen, Bas and Overmeer, Rene and Proost, Natalie and van Tellingen, Olaf and van de Ven, Marieke and Begthel, Harry and Boj, Sylvia F and Clevers, Hans and Roodhart, Jeanine M L and Bos, Johannes L and Snippert, Hugo J G},
  title = {Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer},
  journal = {Cell Reports},
  year = {2023},
  volume = {42},
  number = {4},
  pages = {112324},
  doi = {10.1016/j.celrep.2023.112324}
}
Kostenlos starten →